ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir-Reference-Cited by-同舟云学术

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir

Published:2010-04 Issue:4 Volume:20 Page:217-230
ISSN:1744-6872
Container-title:Pharmacogenetics and Genomics
language:en
Short-container-title:

Author:

Lubomirov Rubin,di Iulio Julia,Fayet Aurélie,Colombo Sara,Martinez Raquel,Marzolini Catia,Furrer Hansjakob,Vernazza Pietro,Calmy Alexandra,Cavassini Matthias,Ledergerber Bruno,Rentsch Katharina,Descombes Patrick,Buclin Thierry,Decosterd Laurent A.,Csajka Chantal,Telenti Amalio

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Genetics(clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics

Reference55 articles.

1. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel;Hammer;JAMA,2008

2. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification;Kumar;Drug Metab Dispos,1999

3. Both P-gp and MRP2 mediate transport of lopinavir, a protease inhibitor;Agarwal;Int J Pharm,2007

4. Pharmacokinetic enhancement of protease inhibitor therapy;King;Clin Pharmacokinet,2004

5. Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice;Molto;Br J Clin Pharmacol,2006

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study;BMC Pharmacology and Toxicology;2023-09-27

2. Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimen;British Journal of Clinical Pharmacology;2023-05-12

3. Pharmacogenomics in cancer;Pharmacogenomics;2023

4. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis;Drug Metabolism and Pharmacokinetics;2022-12

5. Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?;Pharmaceuticals;2022-06-13